Head and Neck, Head and Neck Metastatic
Open, Temporarily Closed
An Open-Label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Eligible for screening study DCP 001
HN007 is temporarily closed to accrual effective June 14, 2021.